The approved accelerator-based BNCT for head and neck cancers in Japan has undergone significant advancement [5]; however, current treatments such as BNCT mediated by 4-borono-L-phenylalanine (L-BPA) are not effective for all patients because of the variability in the expression levels of L-type amino acid transporter 1 (LAT-1), which is responsible for BPA uptake into cancer cells [6]. Here, SLC7A5 is linked to cancer.